Clinical trials: Melanoma of Skin
Melanoma
Avadomide (CC-122) in Combination With Nivolumab in Advanced Melanoma
This study is to find out if the combination of CC-122 (an investigational agent) and Nivolumab will enhance the anti-cancer activity and prevent T-cell exhaustion (T-cells are responsible for maintaining the body's immune…
- Trial name
- NCT03834623
- Testing
- CC-122, Nivolumab
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Malignant Melanoma, Sinonasal Melanoma
Toripalimab Combined With Radiotherapy and Chemotherapy in the Treatment of SNMM After Endoscopic Surgery
Phase II, single-arm, prospective clinical study of Toripalimab(a PD-1 antibody) combined with radiotherapy and chemotherapy in the treatment of sinonasal malignant mucosal melanoma after endoscopic surgery.
- Trial name
- SNMM (NCT04879654)
- Testing
- endoscopic surgery
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Cancer, Breast Cancer
Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
This Phase 1/2 study evaluates the safety, feasibility, and preliminary anti-tumor activity of allogeneic donor-derived CAR-NK cells in participants with advanced solid tumors.
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- SELECT-CAR-NK (NCT07410494)
- Testing
- EB-SELECT Single-Target CAR-NK Cells, Dual-Target Antigen-Selected CAR-NK
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Essen Biotech
Head and Neck Cancer, Cervical Cancer
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05955105
- Testing
- ILB-2109, Toripalimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Innolake Biopharm
Melanoma of Skin, Acral Melanoma
Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial
This is a Phase II clinical trial to evaluate the efficacy and safety of perioperative toripalimab (anti-PD-1) combined with recombinant human endostatin (Endostar) as postoperative adjuvant therapy in patients with clinical…
- Conditions
- Melanoma of Skin, Acral Melanoma, Stage II Melanoma
- Trial name
- FUMS-EDJS2024 (NCT06965231)
- Testing
- Toripalimab combined with Endostar
- Where
- 4 sites in China
- Volunteers
- 58 people
- Sponsor
- Fudan University
Melanoma, Skin Cancer
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
The main purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of XL888 when administered orally with vemurafenib plus cobimetinib in participants with BRAF V600 mutated…
- Trial name
- NCT02721459
- Testing
- XL888, Vemurafenib, Cobimetinib
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Melanoma, Carcinoma, Renal Cell
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer
Background: Recombinant human interleukin-15 (rhIL-15) is a substance that is naturally produced in the body that has many properties that increase the activity and strength of the immune system, the body s natural defense…
- Trial name
- NCT01021059
- Testing
- rh IL-15
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma Stage III, Melanoma Stage IV
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
This research study is studying different immunotherapy regimens as a possible treatment for stage III or IV resectable melanoma.
- Trial name
- NCT04007588
- Testing
- Nivolumab, BMS-986205, Ipilimumab
- Where
- 2 sites in United States
- Sponsor
- Dana-Farber Cancer Institute
Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
This phase II clinical trial studies how well thermal ablation and spine stereotactic radiosurgery work in treating patients with cancer that has spread to the spine (spine metastases) and is at risk for compressing the spinal…
- Conditions
- Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Spine
- Trial name
- NCT02713269
- Testing
- Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Melanoma
Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma
ATLAS-IT-05 was an open-label, single-arm study in patients with advanced melanoma accessible for injections (cutaneous, subcutaneous, lymph node, or intramuscular tumors) and who had either exhausted treatment options or were…
- Trial name
- ATLAS-IT-05 (NCT04796194)
- Testing
- LTX-315 in combination with pembrolizumab
- Where
- 10 sites in United States, France and 2 more
- Volunteers
- 23 people
- Sponsor
- Lytix Biopharma AS
Stage III Skin Melanoma
Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients
This is a two-arm Phase 1b feasibility trial consisting of 20 patients receiving the combination of ipilimumab+nivolumab, either adjuvant, or split neo-adjuvant and adjuvant.
- Trial name
- OpACIN (NCT02437279)
- Testing
- Surgery of the tumor, Infusion with ipilimumab 3 mg/kg q3wks, Infusion with nivolumab 1 mg/kg q3wks
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- The Netherlands Cancer Institute
Melanoma
A Phase I Study of TPI 287 - Temozolomide Combination in Melanoma
The goal of the Phase I portion of this study is to find the highest tolerable dose of TPI 287 that can be given in combination with Temodar (temozolomide) to patients with metastatic melanoma.
- Trial name
- NCT01067066
- Testing
- TPI 287, Temodar (Temozolomide)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Non Small Cell Lung Cancer, Urothelial Cancer
Study of INCB086550 in Select Solid Tumors
An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors
- Conditions
- Non Small Cell Lung Cancer, Urothelial Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
- Trial name
- NCT04629339
- Testing
- INCB086550
- Where
- 20 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 16 people
- Sponsor
- Incyte Corporation
Mucosal Lentiginous Melanoma, Acral Melanoma
Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma
Given the poor prognosis and limited treatment options available for patients with mucosal or acral/lentiginous melanomas who develop metastatic disease, genetic discoveries of KIT mutations in these cancers present the need to…
- Conditions
- Mucosal Lentiginous Melanoma, Acral Melanoma, Melanoma
- Trial name
- NCT00788775
- Testing
- Nilotinib
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Melanoma
Efficacy Study Of P276-00 In Subjects Of Malignant Melanoma Positive For Cyclin D1 Expression
The purpose of this study is to evaluate efficacy of P276-00 in subjects with advanced malignant melanoma positive for cyclin D1 expression
- Trial name
- ENVER (NCT00835419)
- Testing
- P276-00
- Where
- 7 sites in Australia, India and 1 more
- Volunteers
- 12 people
- Sponsor
- Piramal Enterprises Limited
Melanoma (Skin Cancer)
IMmune checkPoint Inhibitor Related gonAdal toxiCiTy in Premenopausal Women and Men With Melanoma
This study aims to capture information regarding the effect of immune checkpoint inhibitor (ICI) treatment for melanoma on reproductive organ function and sex hormone levels.
- Trial name
- IMPACT (NCT07138222)
- Where
- 6 sites in Australia
- Volunteers
- 80 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Melanoma (Skin)
Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis
Melanoma is the deadliest form of skin cancer and its incidence has doubled every 20 years in France, where this cancer is responsible of more than 1600 deaths each year.
- Trial name
- CRIRIN (NCT03949153)
- Testing
- Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Cryotherapy, Ipilimumab Injection
- Where
- France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Strasbourg, France
Breast Cancer, Melanoma
Second Echelon Node Study With Methylene Blue
The investigators plan to study the ability to identify the lymph nodes beyond the sentinel lymph node that may harbor cancer using methylene blue dye.
- Trial name
- NCT01823172
- Testing
- Methylene blue dye injection of sentinel lymph node
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Mayo Clinic
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Advanced Solid Tumor, RAS Mutation
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
This is a Phase 1, First-in-Human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of ABM-168 in adult patients…
- Conditions
- Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
- Trial name
- NCT05831995
- Testing
- ABM-168
- Where
- 6 sites in United States
- Volunteers
- 12 people
- Sponsor
- ABM Therapeutics Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.